Prospective study with patients who have undergone surgery for stage II or III CRC and who receive Signatera testing. Treating clinicians may recommend adjuvant chemotherapy or observation based on test results. BESPOKE CRC is expected to be active at more than 50 sites around the US and is still open to initiate new sites.
See more information at https://clinicaltrials.gov/ct2/show/NCT04264702